Searched for
SUN CIPLA
Sweet pills: How pharma stocks delivered bumper returns to Indian investors, defying 2026 whiplashIndian pharma stocks are outperforming the market, offering strong returns to investors. This resilience is driven by robust domestic deman...- Zaynich's blockbuster potential lifts Wockhardt's long-term outlookWockhardt's novel antibiotic, Zaynich, has received USFDA approval after a 12-year effort, sparking hopes for a turnaround after years of n...
- Q4 earnings review: Motilal Oswal highlights broad-based beat on estimates, lists 6 sectors that exceeded expectationsMotilal Oswal said Q4 FY26 earnings surpassed expectations, with aggregate profits rising 16% year-on-year against its 8% estimate. Strong ...
- Geopolitical stability will decide market’s next move: Sandip SabharwalIndian equity markets are holding above 24,000, buoyed by improving sentiment and steady earnings, though geopolitical tensions remain a co...
- Strong revenue growth fails to shield India Inc margins in March quarterCorporate India's March 2026 quarter results showed a mixed performance. While revenues grew strongly, input cost inflation and a weaker ru...
- Rahul Shah bullish on pharma, sees Sun Pharma and Aurobindo as key large-cap playsIndian equity markets show a mixed but improving consumption trend, with selective FMCG and premium retail outperforming. Page Industries i...
- Mankind, other pharma stocks rally up to 7%; Nifty Pharma scales fresh peak. What lies ahead?Pharma stocks surged on Wednesday, supported by strong earnings and a weakening rupee, even as Sensex and Nifty traded lower. The Nifty Pha...
- Pharma Q4 outlook mixed: Hospitals steady, generics face revlimid dragIndian pharma and healthcare firms face a mixed March quarter. While hospitals anticipate steady growth, generic drugmakers grapple with lo...
- Most hated stocks: FIIs dumping these 146 companies without a break for 4 straight quarters. Do you own any?Foreign institutional investors have been consistently selling shares in 146 Indian companies for four consecutive quarters. This selling s...
- Sun Pharma closes in on Organon buy, gets set for $12 billion binding bidSun Pharmaceutical Industries is nearing a $12 billion acquisition of Organon & Co, marking its most significant overseas expansion. Follow...
- Tariff threat ain't over yet! Sun Pharma, other pharma stocks plunge up to 6%Pharma stocks fell after reports that the Trump administration may impose tariffs—potentially up to 100%—on drugmakers not ensuring low pri...
- Have we missed the bulk of the comeback rally in pharma stocks? Nithya Balasubramanian answers“Sun, Cipla, Lupin being market leaders, should be able to do well. Most of these companies have actually added on the Street last year. Wh...
- Nithya Balasubramanian on 2 pharma names to bet on besides Sun & Cipla“Coming to the complex generics opportunity, Cipla and Lupin are most exposed. We like Cipla more than Lupin because at least in the near t...
- Why Nithya Balasubramanian is gung-ho on Sun Pharma & Cipla“One gets different types of exposure with Sun Pharma and Cipla. For Sun, the capital allocation into US specialty is now bearing fruit. At...
- Sun, Cipla, Gland Pharma should do well in FY23: Nithya Balasubramanian"Sun Pharma shifted focus from generics to speciality, which seems to be doing well. Relatively they have a portfolio that is immune from p...
- Markets in a consolidation phase, should rise again after a pause: Gautam Trivedi, Religare Capital MarketsWe have got an improving inflation situation, and overall macro data is significantly better now than it was the same time last year.
- Cipla and Ranbaxy can appreciate 20% from current price levels: Deven ChokseyCipla and Ranbaxy hold reasonably good chance of appreciating around 20% to 30% from current market price levels.
- Delhi HC extends relief period for pharma cos in drug pricing caseOther companies that have approached the court include Micro Labs, Lupin, Wockhardt, Intas Pharma, Alembic Pharma and Emcure Pharma.
- Sun Pharma recalls 1,55,000 eye solution bottles from USSun Pharma, India's most valuable drug company, is recalling 1,55,000 bottles of an eye solution from the US after impurities were discover...
- Pharmas are quite divided: Deepak Mohoni"Pharmas are quite divided. There are two very strong pharmas at the moment. They are Sun Pharma and Cipla. They are making all the moves."
Load More
